MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX: CXS) (NASDAQ: CXSP) announced today that positive clinical results supporting the development of Ceflatonin® in patients with chronic myeloid leukemia (CML), including patients who had failed treatment with Gleevec® (imatinib mesylate) have been published in Cancer (the journal of the American Cancer Society). Of the five patients who received homoharringtonine (HHT) (Ceflatonin®) at the highest explored dose and were evaluable for response to therapy, all achieved a complete hematological response, including those with the Bcr-Abl kinase domain mutations that confer Gleevec® resistance.
